Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,177,774 papers from all fields of science
Search
Sign In
Create Free Account
AZD 8931
Known as:
AZD-8931
, AZD8931
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Quinazolines
Sapitinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
R. Adams
,
E. Brown
,
+13 authors
T. Maughan
The Lancet Gastroenterology and Hepatology
2017
Corpus ID: 3635835
2016
2016
Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
H. Creedon
,
Laura Gómez-Cuadrado
,
+12 authors
V. Brunton
OncoTarget
2016
Corpus ID: 18530062
Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies in the treatment of HER2-positive breast cancer…
Expand
2016
2016
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast…
S. Johnston
,
M. Basik
,
+7 authors
M. Cristofanilli
Breast Cancer Research and Treatment
2016
Corpus ID: 23861719
PurposeAZD8931 is an orally bioavailable, reversible tyrosine kinase inhibitor of EGFR, HER2, and HER3 signaling. The Phase II…
Expand
2015
2015
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
C. Crafter
,
J. Vincent
,
+4 authors
B. Davies
International Journal of Oncology
2015
Corpus ID: 15126986
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling network is frequently de-regulated…
Expand
Highly Cited
2014
Highly Cited
2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance
G. Morrison
,
Xiaoyong Fu
,
+7 authors
R. Schiff
Breast Cancer Research and Treatment
2014
Corpus ID: 8584898
Modest up-regulation of either HER-ligands or receptors has been implicated in acquired endocrine resistance. AZD8931, a dual…
Expand
2014
2014
E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling
C. Eberlein
,
C. Rooney
,
S. Ross
,
M. Farren
,
H. Weir
,
S. Barry
Oncogene
2014
Corpus ID: 12445712
Fibroblasts in the tumour stroma (cancer-associated fibroblasts) influence tumour progression and response to therapeutics…
Expand
2014
2014
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
S. Tjulandin
,
V. Moiseyenko
,
+5 authors
U. Keilholz
Investigational new drugs
2014
Corpus ID: 21936790
SummaryAim AZD8931 is an oral equipotent inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling. This Phase I, open…
Expand
2014
2014
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
Z. Mu
,
T. Klinowska
,
+4 authors
M. Cristofanilli
Journal of experimental & clinical cancer…
2014
Corpus ID: 17354900
IntroductionEpidermal growth factor receptor (EGFR) overexpression has been associated with prognostic and predictive value in…
Expand
2013
2013
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
B. Barlaam
,
J. Anderton
,
+10 authors
D. Ogilvie
ACS Medicinal Chemistry Letters
2013
Corpus ID: 7989286
Deregulation of HER family signaling promotes proliferation and tumor cell survival and has been described in many human cancers…
Expand
Highly Cited
2010
Highly Cited
2010
AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
D. Hickinson
,
T. Klinowska
,
+13 authors
D. Ogilvie
Clinical Cancer Research
2010
Corpus ID: 1892244
Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE